Vue.component('apd-overview', { template: '
' + '' + '

Antipsychotic Use in Persons with Dementia (APD)

' + '
' + '' + '

Description

' + '
' + '' + '

The percentage of individuals ≥65 years of age with dementia who received an antipsychotic medication without evidence of a psychotic disorder or related condition. (NQF #2111)

' + '

A lower rate indicates better performance.

' + '
' + '' + '

Additional Information

' + '
' + '' + '' + '

Intended Use

' + '
' + '' + '

Performance measurement for health plans.

' + '
' + '
' + '' + '' + '

Data Sources

' + '
' + '' + '

Prescription and medical claims data.

' + '
' + '
' + '' + '' + '

Denominator

' + '
' + '' + "

Individuals with a dementia diagnosis OR ≥2 or prescription claims on different dates of service and >60 days' cumulative supply for any cholinesterase inhibitor or NMDA receptor antagonist during the measurement year.

" + '
' + '
' + '' + '' + '

Exclusions

' + '
' + '' + '

None.

' + '
' + '
' + '' + '' + '

Numerator

' + '
' + '' + '

The number of individuals from the denominator who received an antipsychotic medication without evidence of a psychotic disorder or related condition.

' + '
' + '
' + '
' }); Vue.component('apd-ref-1', { template: '' + 'Ralph SJ, Espinet AJ. Increased All-Cause Mortality by Antipsychotic Drugs: Updated Review and Meta-Analysis in Dementia and General Mental Health Care. J Alzheimers Dis Rep. 2018; 2(1):1-26. PMID: 30480245.' + '1' + '' }); Vue.component('apd-ref-2', { template: '' + 'Szmulewicz AG, Ferraris A, Rodriguez A, et al. All-cause mortality in older adults with affective disorders and dementia under treatment with antipsychotic drugs: A matched-cohort study. Psychiatry Res. 2018; 265:82-86. PMID: 29702305.' + '2' + '' }); Vue.component('apd-ref-3', { template: '' + 'Dennis M, Shine L, John A, et al. Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study. Neurol Ther. 2017; 6(1):57-77. PMID: 28054240.' + '3' + '' }); Vue.component('apd-ref-4', { template: '' + 'Hui TS, Wong A, Wijesinghe R. A review on mortality risks associated with antipsychotic use in behavioral and psychologic symptoms of dementia (BPSD). Ment Health Clin. 2016; 6(5):215-221. PMID: 29955473.' + '4' + '' }); Vue.component('apd-ref-5', { template: '' + 'Maxwell CJ, Campitelli MA, Hogan DB, et al. Relevance of frailty to mortality associated with the use of antipsychotics among community-residing older adults with impaired cognition. Pharmacoepidemiol Drug Saf. 2018; 27(3):289-298. PMID: 29318705.' + '5' + '' }); Vue.component('apd-ref-6', { template: '' + 'Nielsen RE, Lolk A, Valentin JB, Andersen K. Cumulative dosages of antipsychotic drugs are associated with increased mortality rate in patients with Alzheimer’s dementia. Acta Psychiatr Scand. 2016; 134(4):314-20. PMID: 27357602.' + '6' + '' }); Vue.component('apd-ref-7', { template: '' + 'Nielsen RE, Lolk A, M Rodrigo-Domingo, et al. Antipsychotic treatment effects on cardiovascular, cancer, infection, and intentional self-harm as cause of death in patients with Alzheimer’s dementia. Eur Psychiatry. 2017; 42:14-23. PMID: 28199869.' + '7' + '' }); Vue.component('apd-ref-8', { template: '' + 'Sahlberg M, Holm E, Gislason GH, et al. Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons. J Am Heart Assoc. 2015 ; 4(9):e001666. PMID: 26330335.' + '8' + '' }); Vue.component('apd-ref-9', { template: '' + 'Simoni-Wastila L, Wei YJ, Lucas JA, et al. Mortality Risk of Antipsychotic Dose and Duration in Nursing Home Residents with Chronic or Acute Indications. J Am Geriatr Soc. 2016; 64(5):973-80. PMID: 27166586.' + '9' + '' }); Vue.component('apd-ref-10', { template: '' + 'Liperoti R, Sganga F, Landi F, et al. Antipsychotic Drug Interactions and Mortality Among Nursing Home Residents With Cognitive Impairment. J Clin Psychiatry. 2017; 78(1):e76-e82. PMID: 28129493.' + '10' + '' }); Vue.component('apd-ref-11', { template: '' + 'Tolppanen AM, Taipale H, Tanskanen A, et al. Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease - exposure-matched cohort study. BMC Geriatr. 2016; 16(1):204. PMID: 27908278.' + '11' + '' }); Vue.component('apd-ref-12', { template: '' + 'Nerius M, Johnell K, Garcia-Ptacek S, et al. The Impact of Antipsychotic Drugs on Long-term Care, Nursing Home Admission, and Death in Dementia Patients. J Gerontol A Biol Sci Med Sci. 2018; 73(10):1396-1402. PMID: 29228107.' + '12' + '' }); Vue.component('apd-ref-13', { template: '' + 'Hulshof TA, Zuidema SU, van Meer PJK, et al. Baseline imbalances and clinical outcomes of atypical antipsychotics in dementia: A meta-epidemiological study of randomized trials. Int J Methods Psychiatr Res. 2018; e1757. PMID: 30515916.' + '13' + '' }); Vue.component('apd-ref-14', { template: '' + 'Brännström J, Boström G, Rosendahl E, et al. Psychotropic drug use and mortality in old people with dementia: investigating sex differences. BMC Pharmacol Toxicol. 2017; 18(1):36. PMID: 28545507.' + '14' + '' }); Vue.component('apd-ref-15', { template: '' + 'Yunusa I, Alsumali A, Garba AE, et al. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Netw Open. 2019; 2(3):e190828. PMID: 30901041.' + '15' + '' }); Vue.component('apd-ref-16', { template: '' + 'Bo M, Ceccofiglio A, Mussi C, et al. Prevalence, predictors and clinical implications of prolonged corrected QT in elderly patients with dementia and suspected syncope. Eur J Intern Med. 2018. pii: S0953-6205(18)30404-7. PMID: 30482635.' + '16' + '' }); Vue.component('apd-ref-17', { template: '' + 'Sharma S, Mueller C, Stewart R, et al. Predictors of Falls and Fractures Leading to Hospitalization in People With Dementia: A Representative Cohort Study. J Am Med Dir Assoc. 2018; 19(7):607-612. PMID: 29752159.' + '17' + '' }); Vue.component('apd-ref-18', { template: '' + 'Haque R, Alavi Z. Assessing the Impact of an Interdisciplinary Team Approach Using the ARMOR Protocol on the Rate of Psychotropic Medications and Other Quality Indicators in Long-Term Care Facilities. Ann Longterm Care. 2019; 27(5):24-31.' + '18' + '' }); Vue.component('apd-ref-19', { template: '' + 'Johnell K, Jonasdottir Bergman G, Fastbom J, et al. Psychotropic drugs and the risk of fall injuries, hospitalisations and mortality among older adults. Int J Geriatr Psychiatry. 2017; 32(4):414-420. PMID: 27113813.' + '19' + '' }); Vue.component('apd-ref-20', { template: '' + 'Lapeyre-Mestre M. A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia. Drugs Aging. 2016; 33(12):865-888. PMID: 27812994.' + '20' + '' }); Vue.component('apd-ref-21', { template: '' + 'Arai H, Nakamura Y, Taguchi M, Kobayashi H, Yamauchi K, Schneider LS; J-CATIA Study Group. Mortality risk in current and new antipsychotic Alzheimers disease users: Large scale Japanese study. Alzheimers Dement. 2016; 12(7):823-30. PMID: 27106669.' + '21' + '' }); Vue.component('apd-rationale', { template: '
' + '' + '

Rationale

' + '
' + '' + '

Antipsychotics have been used to help manage behavioral and psychological symptoms of dementia (BPSD).' + '' + ' While the use of antipsychotics have been effective in managing BPSD, there have also been serious concerns regarding antipsychotic use in individuals with dementia.' + ',' + ' For example, there is increased mortality risk associated with use of antipsychotics in people with dementia, resulting in the FDA placing a black-box warning on atypical antipsychotics in 2005 and on conventional antipsychotics in 2010.' + '' + ' Current literature has expanded on these concerns and have demonstrated increased mortality and increased morbidity with antipsychotic use in older adults.' + ',,' + ',,' + ',,' + ',,' + ',,' + ',,' + '' + ' The terms "elderly" and "older adults" have historically been defined as individuals aged 65 years and older. Current literature still uses this definition when evaluating antipsychotic use in older adults with dementia.' + '' + ' However, on the other hand, there have also been literature that has challenged the data supporting the association of antipsychotics with morbidity and mortality.' + '' + '

' + '

There is growing public concern about psychotropic use in older adults. Previous studies have identified higher rates of mortality when patients with dementia are treated with antipsychotic agents, but more recent studies of older adults have demonstrated that this increased risk is seen in all users of antipsychotics, not just those with dementia.' + ',' + ' Multiple studies have shown that this increased risk in mortality is dose-related, and many have demonstrated that the risk is highest within the 30 days of antipsychotic exposure.' + ',' + ',,' + ',,' + ',,' + '' + ' The presence of drug interactions, particularly with cardiovascular agents, antibiotics, other psychotropics, sulfonylureas, theophylline, warfarin, and nonsteroidal anti-inflammatory drugs are also likely contributing to this increased risk.' + '' + '

' + '

Concerns of morbidity related to antipsychotic use in older adults are also increasing. Antipsychotic use has been shown to increase risk of deep vein thrombosis, pulmonary embolism, stroke, and hip fracture' + '' + '; and the risk of hip fracture may even be higher in older adults without dementia.' + '' + ' Antipsychotic use has been shown to be associated with long-term care dependence and nursing home admissions.' + '' + " Additionally, there is the possibility that randomized controlled trials have been overestimating efficacy of antipsychotics while underestimating risk of extrapyramidal symptoms due to the trials' imbalances in baseline characteristics." + '' + ' This notion is further highlighted by a recent network meta-analysis that suggests that atypical antipsychotics offer only a modest benefit over placebo, but is associated with significant safety risks.' + '' + '

' + 'There are newer studies that challenge previous data supporting the association of antipsychotics with morbidity and mortality. In a study of combined data from Sweden and Finland, antipsychotic use was not associated with elevated mortality risk.' + '' + ' Frailty is one confounding variable that is cited repeatedly in studies evaluating this risk with antipsychotics.' + ',,' + ' In a sample of older adults with dementia from an Italian dataset, antipsychotic drugs were not associated with prolonged QT interval.' + '' + ' In a cohort study of dementia patients who had experienced falls, psychotropics and antipsychotics were not shown to be a predictor of falls leading to hospitalization.' + '' + ' Moreover, Haque et al actually demonstrated that a reduction in antipsychotic use was associated with increased risk of falls and reported pain.' + '' + ' Although the increased rates of falls and reported pain were not statistically significant from baseline to intervention, this finding provides an important perspective to consider regarding the unexpected consequences of increased scrutiny and regulation of antipsychotics. Nevertheless, these aforementioned studies conflict with existing literature demonstrating psychotropics increasing risk of falls, hospitalizations, and death in all older adults.' + ',,' + ' Other studies have shown that duration of antipsychotic use longer than six months is associated with lower mortality risk.' + ',' + ' These conflicts demonstrate the need for further evaluation of the use of psychotropic medications in older adults and their associated consequences.' + '

' + '

Although recent literature has challenged the association of antipsychotics with morbidity and mortality, there is still a large body of literature that demonstrates morbidity and mortality risk with antipsychotic use in older adults. As such, this measure is appropriate to monitor and improve the quality of care in older adults with dementia.

' + '
' + '
' }); Vue.component('apd-faqs', { template: '
' + '' + '

FAQs

' + '
' + '' + '' + '' + '' + "
The intent of the measure is to assess the first treatment within the measurement year, as it is too complex to assess retreatment with the same or different antiviral medication during the same measurement year. Only the first treatment within the measurement year, based upon the IPSD, should be evaluated for the numerator to determine if the individual received the cumulative days' supply required to complete the minimum duration of therapy and if the individual did not have a cumulative gap of >15 days between the first and the last fills.
" + '
' + '' + '' + '
' + '
    ' + '
  1. Determine the earliest date of service, or index prescription start date (IPSD), for a direct-acting antiviral (DAA) medication used to treat Hepatitis C during the measurement year.
  2. ' + '
  3. Determine the last fill required to meet the minimum duration of therapy for the same DAA medication. Note: If the individual did not complete the minimum duration of therapy, then the individual does not meet the numerator criteria and there is no need to evaluate the cumulative gap. Also, additional fills that occur after the last fill required to meet the minimum duration of therapy should not be included when calculating the cumulative gap.
  4. ' + '
  5. Within this period, identify the days that the individual was covered by the DAA medication based on the prescription fill date and days of supply. If prescriptions for the same DAA medication overlap, then adjust the prescription start date to be the day after the previous fill has ended. Then, count the days that the individual was not covered by the DAA medication.
  6. ' + '
' + '
' + '
' + '
' + '
' + '
' }); Vue.component('apd', { template: '
' + '' + '' + /*'' +*/ '



' + '
', props: { rationale: { default: false }, faqs: { default: false } } });